EMEA-001207-PIP02-19-M01
Key facts
Invented name |
Gazyvaro
|
Active substance |
Obinutuzumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0296/2022
|
PIP number |
EMEA-001207-PIP02-19-M01
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|